Home
Live Updates
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates : comparemela.com
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...
Related Keywords
Zhejiang ,
China ,
Hong Kong ,
United States ,
Hangzhou ,
Suzhou ,
Jiangsu ,
Chicago ,
Illinois ,
Guangzhou ,
Guangdong ,
Jilin ,
Rockville ,
Melbourne ,
Victoria ,
Australia ,
Chinese ,
American ,
Yuxiang Ma ,
Haibo Qiu ,
Masa Lasica ,
Prnewswire Ascentage Pharma ,
Huafeng Wang ,
Ascentage Pharma ,
Yifan Zhai ,
Md Anderson Cancer Center ,
American Society Of Clinical Oncology ,
Sun Yat Sen University Cancer Center ,
Zhejiang University School Of Medicine ,
Major National ,
Dana Farber Cancer Institute ,
China National Medical Products Administration ,
National Reimbursement Drug List ,
Astrazeneca ,
Clinical Oncology ,
Annual Meeting ,
Oral Reports ,
Chief Medical Officer ,
Central Time ,
Hematologic Malignancies ,
Myelodysplastic Syndromes ,
First Affiliated Hospital ,
Zhejiang University School ,
Chronic Lymphocytic ,
Developmental Therapeutics ,
Molecularly Targeted Agents ,
Main Board ,
Stock Exchange ,
Hong Kong Limited ,
Major National Rd Projects ,
Major New Drug Projects ,
New Drug Incubator ,
Innovative Drug Programs ,
Major Project ,
Priority Review Designations ,
Breakthrough Therapy Designations ,
Drug Evaluation ,
Reimbursement Drug List ,
Orphan Drug Designation ,
Fast Track Designation ,
Orphan Designation ,
Cancer Center ,
Mayo Clinic ,
comparemela.com © 2020. All Rights Reserved.